Patients in a Phase 3 clinical trial who received sotorasib and panitumumab lived longer, suggesting the combination therapy could become the new standard of care, according to a new City of Hope study. LOS ANGELES, Calif. — A novel combination therapy offers better outcomes for patients with KRAS G12C metastatic...
treatment News
TAIPEI — Foresee Pharmaceuticals (TPEx: 6576), (“Foresee”) today announces that the first patient has been dosed in the Casppian Phase 3 registration study. “The Casppian Phase 3 study is an open-label, multicenter clinical trial to evaluate the efficacy, safety, and pharmacokinetics of leuprolide (FP-001) 42 mg-controlled release in patients with...
TAIPEI, Taiwan — Foresee Pharmaceuticals (TPEx: 6576), announced the positive safety review by the independent Data and Safety Monitoring Board for its Casppian Phase 3 registration study. The DSMB recommended that Foresee Pharmaceuticals continue the trial with a minor amended protocol. The Casppian Phase 3 study is an open-label, multicenter,...
TAIPEI— Foresee Pharmaceuticals (TPEx: 6576), (“Foresee”) announced today that the company will be presenting at the American Heart Association (AHA) 2023 Annual Meeting taking place in Philadelphia, PA, from November 11-13, 2023. The presentation will focus on Foresee’s first-in-class oral ALDH2 activator, FP-045, and the clinical design of Phase 2...
COLUMBUS, Ohio — Forge Biologics (Forge), a member of Ajinomoto Bio-Pharma Services and a leading manufacturer of genetic medicines, announced a clinical update today on five patients with Krabbe disease that have received FBX-101, an AAV gene therapy, after hematopoietic stem cell transplantation (HSCT). Timothy J. Miller, Ph.D., CEO and...
WATERTOWN, Mass. – Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced new data from its ongoing randomized, placebo-controlled, multi-center Phase 1 trial of FT-4202 in patients with sickle cell disease (SCD) that further support the development of this novel investigational agent,...
Philadelphia, PA – FORTE (NRG-CC005) is a highly anticipated colorectal cancer prevention trial led by NRG Oncology examining surveillance colonoscopy intervals in participants who have non-advanced polyps. Expected to enroll 9,500 participants (about 4,750 people in each study group), we are excited to announce that FORTE accrued its 1000th participant...
LONDON, England — Freeline Therapeutics today announced new clinical data from its ongoing Phase 1/2 GALILEO-1 trial of FLT201, its adeno-associated virus (AAV) gene therapy candidate for Gaucher disease, showing substantial reductions in glucosylsphinogsine (lyso-Gb1), one of the best predictors of clinical response, in patients with persistently high levels despite...
SOUTH SAN FRANCISCO, Calif. — Freenome, a biotechnology company pioneering an early cancer detection platform, today announced topline results from PREEMPT CRC, a prospective, registrational clinical study to validate its blood-based test for the early detection of colorectal cancer (CRC) among average-risk adults. In a prespecified analysis, the Freenome blood...
Shenzhen, China – This study is led by Dr. Weiren Huang (Shenzhen Institute of Translational Medicine, the First Affiliated Hospital of Shenzhen University). In clinical practice, drug resistance poses a significant challenge in cancer treatment. The process of developing resistance is regulated by complex decision-making pathways and genetic signal networks....